ADARx Pharmaceuticals Inc.’s Post

This morning, we published our Full Year 23 and First Quarter Financial Results. In addition, we have published our Annual Report, this year, augmented by a fifth standalone book for Sustainability Report. CEO Jean-Paul Clozel summarized, “2023 was a year of adaptation for Idorsia. And during 2023, we made great progress with expanding the availability of our insomnia drug and patient access in the US, Canada, and across Europe. The drug is rapidly being recognized by specialists as a major advance in the field of insomnia. In 2024, we have already reached multiple significant milestones with the deal with Viatris and an arrangement with holders of the convertible bond 2024 due for repayment in July. Lastly, the quality of our research and development engine was once again confirmed by the FDA’s approval of our new drug in the US. This will now unlock value for Idorsia as we evaluate possible launch strategies – including potential partnership – for the first antihypertensive working on a new pathway seen in almost 40 years.” We will be hosting a webcast at 14:00 CET. Join us to hear from our CEO, Jean-Paul Clozel and CFO, Andre Muller. Read more here: https://bit.ly/idiamr See the Annual Reports here: https://bit.ly/IDIA-AR

Explore the importance of a well-defined single IRB (sIRB) action plan in Advarra's upcoming webinar with experts, Joshua Fedewa and Adam J McClintock. Stay ahead of the curve and ensure your research operations are compliant and efficient. Reserve your seat today! #clinicaltrials #clinicalresearch

Value-based contracts (also called outcome-based agreements) are becoming increasingly common. These agreements share financial risk associated with new treatments by tying drug cost to treatment performance.   However, there is a challenge: value-based contracts are only needed when there is disagreement about how a treatment will actually perform for a given population. For effective negotiation, parties need to understand the likelihood and the financial impact of different performance scenarios. Working with NEWDIGS Initiative at Tufts Medical Center we developed #VBCAM (Value-Based Contract impact Assessment Model) to do just that. Using a Bayesian approach, VBCAM integrates existing evidence with expert beliefs to help each party understand their risk.   Check-out our recent poster at #ISPOR2024 to learn more about VBCAM ⤵. You can also try the tool for yourself: https://lnkd.in/geaQ7z7m   #VBC #OBA #Value #Bayesian #RareDiseases #CellGeneTherapies #CGT

Vivani Medical ( $VANI ) social hype OVER HYPED. Current odds of financial turmoil is under 22%: Vivani Medical employs about 50 people. The company is managed by 6 executives with a total tenure of roughly 117 years, averaging almost 19.0 years of service per executive, having 8.33 employees per reported executive. Vivani Medical retains market capitalization of 157.67 m. Vivani Medical is selling for under 3.09. That is -26.78 percent decrease. Started trading at 4.22. https://lnkd.in/gzQNaJxH #trading #ideas #stocks

Great development and news from Chordate Medical AB “There are several types of buyers” – Chordate CEO Anders Weilandt on Biostock Chordate CEO Anders Weilandt talks with Biostock about the last stage of the company’s exit strategy, Ozilia’s position within the migraine market, and the recent migraine market authorization in Saudi Arabia. When can the shareholders expect an exit? “All we can say is we’ve decided now that we’ve built up enough substance in our prior four steps in the strategy to reach this point where the assignment of Partner International is sensible to start.” And Saudi Arabia will be a perfect proof of concept for this process? “Yes, Saudi Arabia is a perfect proof of concept, and the reason is the fact that we’ve come so far. We have governmental approval for the product in public healthcare. We have reimbursement from major global insurance companies. And those are tick boxes of what you like to see when you are looking at market penetration. So Saudi Arabia, right now, is in the lead of our proof building.” What kind of buyer will be the perfect fit, considering the huge potential that Chordate has? “The perfect buyer is of course someone with the highest valuation of the opportunity. Obviously, that could be a buyer in the medtech field, certainly in the neuromodulation or the neuro diagnostic field. They do exist in the medtech industry. It could of course be someone in the pharma industry, certainly with some mix of business models. But there is also a third one, and that is portfolio building companies that are financially driven, that build up strong therapy focused companies for probably a later divestiture. So, there are a number of types of buyers.” https://lnkd.in/eCTzcp_H British Association for the Study of Headache Anders Weilandt

Looking forward to an insightful panel discussion with LeeAnn Ali

If you’re heading to DIA 2024, don’t miss IQVIA’s Barbara Arone and WEP Clinical’s Ana Tediosi as they discuss the complexities of Pre-Approval Access (PAA). Focusing on key decisions and success factors, this session will highlight pragmatic decisions that play into the development of efficient Pre-Approval Access programs, and address considerations and challenges for the provision of investigational products to patients outside of clinical trials. https://bit.ly/3yCE5cd #DIA2024

Looking forward to an insightful panel discussion with LeeAnn Ali

Dear MedVector Friends and Stakeholders, Great news, the industry seems to be at a tipping point, and we wanted to open the doors to smaller investors before the VC frenzy begins. ($500 minimum) Since our last StartEngine round, we've made a lot of progress in the buildout of MedVector. Specifically, we've: • Raised $1.5M from larger investors, for a total of $3.5 million total invested. • Signed NDAs with 9 of the top 15 pharmaceutical companies, with several proposals out. • Are the official partner of the State of Delaware for clinical research. During our last round, our valuation was $10M; today, the cap is $25M, so our early investors are doing great! If you'd like to participate, learn more, or simply watch our momentum grow, check out our campaign page below! (Note: Existing investors and early investors get bonuses.) All the best, Scott Stout MedVector CEO https://lnkd.in/edhdwiPk

📅 The 8th Annual Operational Excellence in Clinical Trials Summit is fast approaching. Our Central Monitor Consultant, Melissa Thomas, will share her expertise on Feasibility Challenges, Site Operations and Clinical Innovation on September 25th at 12:40pm. Get ready for actionable insights that can transform your clinical trial operations. Don’t miss it: https://lnkd.in/ep7tkvcP #ClinicalTrials #OpEx #ClinicalResearch #ClinicalOperations